Vol 3 (April 2022): Translational Breast Cancer Research

Editorial Commentary 
New progress in early breast cancer treatment in 2021
Bo Shen, Ciqiu Yang, Kun Wang
Translational Breast Cancer Research  
2022;
3:
20  
Case Report 
Pseudoangiomatous stromal hyperplasia causing massive unilateral breast enlargement—a case report
Arjuna Brodie, Ahmed Eltatawy, Kelly Lambert
Translational Breast Cancer Research  
2022;
3:
19  
Review Article 
Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
Ying Yan, Qiao Li, Jianbin Li
Translational Breast Cancer Research  
2022;
3:
18  
Review Article 
Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer
Yan Zhou, Jin Yang
Translational Breast Cancer Research  
2022;
3:
17  
Review Article 
Narrative review of progress in pathological diagnosis of breast cancer
Yueping Liu
Translational Breast Cancer Research  
2022;
3:
16  
Original Article 
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study
Tao Wang, Pin Zhang, Lijun Di, Xiaojia Wang, Junlan Yang, Zhongsheng Tong, Jian Liu, Jifeng Feng, Donggeng Liu, Qitao Yu, Yunpeng Liu, Hao Yu, Zefei Jiang
Translational Breast Cancer Research  
2022;
3:
15  
Original Article 
The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients
Qing Wang, Dechun Yang, Jialin Mei, Sijia Li, Siqi Xie, Hengyu Zhang, Lanyi Dai, Ziyu Zhu, Yafeng Lv, Fuying Yang, Dequan Liu, Rong Guo, Shicong Tang
Translational Breast Cancer Research  
2022;
3:
14  
Guideline 
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Zefei Jiang, Jianbin Li, Jiayi Chen, Yueping Liu, Kun Wang, Jianyun Nie, Xiaojia Wang, Chunfang Hao, Yongmei Yin, Shusen Wang, Min Yan, Tao Wang, Ying Yan, Xiaoyuan Chen, Erwei Song; CSCO BC guideline working group
Translational Breast Cancer Research  
2022;
3:
13  
Editorial 
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: adjuvant therapy for triple negative breast cancer in 2022
Hua Ding, Li Zhang, Yue Wang, Shu Liu
Translational Breast Cancer Research  
2022;
3:
12  
Editorial 
Escalating and de-escalating treatments in HR+HER2− early-stage breast cancer
Rui Ge
Translational Breast Cancer Research  
2022;
3:
11  
Editorial 
CDK4/6 inhibitors combined with fulvestrant for HR+/HER2 advanced breast cancer
Jie Zhang, Chunfang Hao
Translational Breast Cancer Research  
2022;
3:
10